Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 146

Sort by

Sort Order Select

Journal Articles

Dose-Dependent Iron Chelating Effects of Eltrombopag on in Vitro Human Megakaryopoiesis

Zhi-Jian Liu, PhD, Emoke Deschmann, MD, Haley E. Ramsey, PhDMSc, Henry Feldman, Bethan Psaila, MD PhD, Nichola Cooper, MD MRCP, Evangelia Vlachodimtropoulou Koumoutsea, MBBS,PhDBSc, John B. Porter, MA MDFRCP FRCPath, James B. Bussel, MD, Michael Georgieff, MD, Martha Sola-Visner, MD

Blood (2019) 134 (Supplement_1): 2475.

https://doi.org/10.1182/blood-2019-131895

Published: 2019

Journal Articles

The Burden of Disease and IMPACT of Immune Thrombocytopenia (ITP) on Patients: Results from an ITP Survey

James B. Bussel, MD, Alexandra Kruse, Caroline Kruse, Jody Shy, Kavita Aggarwal, PharmD, Michael Vredenburg, PhD, Keith R McCrae, MD

Blood (2019) 134 (Supplement_1): 1076.

https://doi.org/10.1182/blood-2019-131351

Published: 2019

Journal Articles

Safety and Efficacy of the Off-Label Use of Thrombopoietin Receptor Agonists for Immune Thrombocytopenia in Pregnancy: Results from a Multicentre Observational Study

Marc Michel, Marco Ruggeri, Tomás José González-López, MD, Stephane Cheze, MD, Waleed Ghanima, MD PhD, Tor Henrik Anderson Tvedt, Mikael Ebbo, MD PhD, James B. Bussel, MD, Bertrand Godeau, MD

Blood (2019) 134 (Supplement_1): 1081.

https://doi.org/10.1182/blood-2019-122595

Published: 2019

Journal Articles

Potential Anti-Thrombotic Effect without Accompanying Hemorrhage with Fostamatinib Use in Patients with Immune Thrombocytopenia

Ivy Altomare, MD, Vadim V. Markovtsov, PhD, Leslie Todd, Dheepika Weerasinghe, PhD, Robert P. Numerof, PhD, Sandy Tong, MD, Esteban Masuda, PhD, James B. Bussel, MD

Blood (2019) 134 (Supplement_1): 4889.

https://doi.org/10.1182/blood-2019-126558

Published: 2019

Journal Articles

Rozanolixizumab, an Anti-FcRn Antibody: Final Results from a Phase II, Multiple-Dose Study in Patients with Primary Immune Thrombocytopenia

Tadeusz Robak, MD, Maciej Kaźmierczak, Isidro Jarque, Vasile Musteata, MD PhD, Jacek Trelinski, Nichola Cooper, MD MRCP, Peter Kiessling, Ute Massow, Franz Woltering, Rose Snipes, Juan Ke, Grant Langdon, Birgit Haier, James B. Bussel, MD, Stephen Jolles

Blood (2019) 134 (Supplement_1): 897.

https://doi.org/10.1182/blood-2019-129839

Published: 2019

Journal Articles

Mental Health and Treatment in Patients with Immune Thrombocytopenia (ITP); Data from the Platelet Disorder Support Association (PDSA) Patient Registry

Alexandra Kruse, Caroline Kruse, Nancy Potthast, Kelsey Milligan, James B. Bussel, MD

Blood (2019) 134 (Supplement_1): 2362.

https://doi.org/10.1182/blood-2019-122278

Published: 2019

Journal Articles

Physicians' and Patients' Perspectives on Treatments in ITP - a Multi-Country Perspective: Results from the ITP World Impact Survey (I-WISh)

James B. Bussel, MD, Waleed Ghanima, MD PhD, Yoshiaki Tomiyama, MD, Donald M. Arnold, MD, Drew Provan, MD, Ming Hou, MD PhD, Cristina Santoro, MD PhD, Serge Laborde, Alexandra Kruse, Caroline Kruse, Mervyn Morgan, Barbara Lovrencic, John Waller, PhD, Jens Haenig, Nichola Cooper, MD MRCP

Blood (2019) 134 (Supplement_1): 1097.

https://doi.org/10.1182/blood-2019-130591

Published: 2019

Journal Articles

Enhanced Responses to Fostamatinib As Second-Line Therapy and in Persistent Immune Thrombocytopenia (ITP) Patients

Ralph Boccia, MD, Michael A. Boxer, MD, Waleed Ghanima, MD PhD, Quentin A. Hill, Michelle Sholzberg, MDBSc,FRCPC,MSc, Michael D. Tarantino, MD, Yuliya Kreychman, PharmD, Robert P. Numerof, PhD, Brian Olender, BA, Leslie Todd, Sandy Tong, MD, Anne-Marie Duliege, MDMS, Nichola Cooper, MD MRCP, James B. Bussel, MD

Blood (2019) 134 (Supplement_1): 1069.

https://doi.org/10.1182/blood-2019-126473

Published: 2019

Journal Articles

Hyper-Sialylated IgG M254, an Innovative Therapeutic Candidate, Evaluated in Healthy Volunteers and in Patients with Immune Thrombocytopenia Purpura: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics

Santiago Arroyo, MD PhD, Renger G Tiessen, MD, William S Denney, PhD, Jim Jin, MS, Mattheus Paulus (Thijs) van Iersel, MD, Heidi Zeitz, MD CCRA, Anthony M Manning, PhD, Martin R. Schipperus, MD PhD, James B. Bussel, MD

Blood (2019) 134 (Supplement_1): 1090.

https://doi.org/10.1182/blood-2019-125993

Published: 2019

Journal Articles

Updated Results from the Single-Arm, Open-Label, Long-Term Efficacy and Safety Study of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP)

John Grainger, MD MRCP, FRPATH, James B. Bussel, MD, Michael D. Tarantino, MD, Nichola Cooper, Donald Beam, Jenny M. Despotovic, DO, Alexey A. Maschan, MD, Kejia Wang, PhD, Melissa Jeanne Eisen, MD, Charles Bowers, MD

Blood (2019) 134 (Supplement_1): 1095.

https://doi.org/10.1182/blood-2019-131241

Published: 2019

Journal Articles

Rituximab (Ritux) Maintenance Infusions in Immune Thrombocytopenia (ITP) to Prolong Remission Following Relapse after Initial Ritux Induction but Responded to a Second Course

Manoj P Rai, MD, Eun-Ju Lee, MD, James B. Bussel, MD

Blood (2018) 132 (Supplement 1): 3753.

https://doi.org/10.1182/blood-2018-99-114242

Published: 2018

Journal Articles

Therapeutic Plasma Exchange Practices in Immune Thrombocytopenic Purpura Related Hospitalizations: Real World Practices for a Category III Apheresis Indication

Sarah Makhani, BA, Joseph Schwartz, MD MPH, Aaron Tobian, MD PhD, Saurav Chopra, Ljiljana V. Vasovic, MD, Robert Andrew Desimone, MD, Patricia Shi, MD, Shipra Kaicker, MD, Cassandra D Josephson, MD, James B. Bussel, MD, Ruchika Goel, MD MPH

Blood (2018) 132 (Supplement 1): 3757.

https://doi.org/10.1182/blood-2018-99-111425

Published: 2018

Journal Articles

Thrombin-Generating Capacity of Microvesicles (MVs) in Patients with Immune Thrombocytopenia (ITP) before and during Treatment with Thrombopoietin-Receptor Agonists (TPO-RA)

Lamya Garabet, Waleed Ghanima, MD PhD, Marit Hellum, Per Morten Sandset, James B. Bussel, MD, Carola E. Henriksson

Blood (2018) 132 (Supplement 1): 2511.

https://doi.org/10.1182/blood-2018-99-116911

Published: 2018

Journal Articles

Immune Thrombocytopenia Complications: Implications on Length of Stay and and Mortality

Manoj P Rai, MD, Prabhjot Singh Bedi, MD, Justin D. Kaner, MD, Prajwal Dhakal, MBBS, Samanjit Kaur Kandola, MD, Nishant Tageja, MD, Heather Laird-Fick, MD, Marwan S Abougergi, MD, James B. Bussel, MD, Stanley M. Marks, MD

Blood (2018) 132 (Supplement 1): 3512.

https://doi.org/10.1182/blood-2018-99-115825

Published: 2018

Journal Articles

Venous Thromboembolism (VTE) in Hematological and Non-Hematological Cancers: A Nationwide Analysis

Manoj P Rai, MD, Prabhjot Singh Bedi, MD, Justin D. Kaner, MD, Samanjit Kaur Kandola, MD, Konchok Norgais, MD, Nishant Tageja, MD, Heather Laird-Fick, MD, James B. Bussel, MD, Stanley M. Marks, MD, Marwan S Abougergi, MD

Blood (2018) 132 (Supplement 1): 3563.

https://doi.org/10.1182/blood-2018-99-115839

Published: 2018

Journal Articles

Predictors of Remission in Adults with Immune Thrombocytopenia Treated with Romiplostim

Adrian Newland, MA, FRCP, FRCPath, James B. Bussel, MD, Robert Bird, FRACP, FRCP, FRCPA, MBBS, MRCP, Donald M. Arnold, MD MSc, FRCPC, Craig M. Kessler, Jiří Mayer, Monica Tejeda Romero, Ann Janssens, Kejia Wang, PhD, Melissa Jeanne Eisen, MD

Blood (2018) 132 (Supplement 1): 735.

https://doi.org/10.1182/blood-2018-99-109791

Published: 2018

Journal Articles

Two-Year Safety and Efficacy Outcomes with Fostamatinib in Adult Patients with Immune Thrombocytopenia (ITP): Open-Label Extension to Phase 3 Trial Program

Anne-Marie Duliege, MDMS, Donald M. Arnold, MD MSc, FRCPC, Ralph Boccia, MD, Michael Boxer, MD, Nichola Cooper, MRCP, Quentin A Hill, BSc, MBChB, MRCP, FRCPath, Darla K Liles, MD, Michelle Sholzberg, MDM, MSc, FRCPC, Hany Zayed, PhD, Sandra Tong, MD, James B. Bussel, MD

Blood (2018) 132 (Supplement 1): 736.

https://doi.org/10.1182/blood-2018-99-110482

Published: 2018

Journal Articles

Treatment of Immune Thrombocytopenia (ITP) with Eltrombopag (EPAG) in Patients Who Did and Did Not Receive Prior Rituximab (Ritux): A Post-Hoc Analysis of the Extend Study

Oliver Meyer, James B. Bussel, MD, Raymond S Wong, MBChB, MD, Abderrahim Khelif, Miona Stankovic, Joan Maier, Mansoor N. Saleh

Blood (2018) 132 (Supplement 1): 1152.

https://doi.org/10.1182/blood-2018-99-114694

Published: 2018

Journal Articles

Medical Decision Analysis: Choosing Second Line Treatment in Adults with Immune Thrombocytopenia (ITP)

Barbara Skopec, MD PhD, Hollenberg P. James, MD, James B. Bussel, MD

Blood (2018) 132 (Supplement 1): 4986.

https://doi.org/10.1182/blood-2018-99-120346

Published: 2018

Journal Articles

Fetal-Neonatal Alloimmune Thrombocytopenia (FNAIT): Guidance to Reduce the Risk of Intracranial Bleeding

Blood (2018) 132 (Supplement 1): 4717.

https://doi.org/10.1182/blood-2018-99-109906

Published: 2018

NARROW

Dose-Dependent Iron Chelating Effects of Eltrombopag on in Vitro Human Megakaryopoiesis

The Burden of Disease and IMPACT of Immune Thrombocytopenia (ITP) on Patients: Results from an ITP Survey

Safety and Efficacy of the Off-Label Use of Thrombopoietin Receptor Agonists for Immune Thrombocytopenia in Pregnancy: Results from a Multicentre Observational Study

Potential Anti-Thrombotic Effect without Accompanying Hemorrhage with Fostamatinib Use in Patients with Immune Thrombocytopenia

Rozanolixizumab, an Anti-FcRn Antibody: Final Results from a Phase II, Multiple-Dose Study in Patients with Primary Immune Thrombocytopenia

Mental Health and Treatment in Patients with Immune Thrombocytopenia (ITP); Data from the Platelet Disorder Support Association (PDSA) Patient Registry

Physicians' and Patients' Perspectives on Treatments in ITP - a Multi-Country Perspective: Results from the ITP World Impact Survey (I-WISh)

Enhanced Responses to Fostamatinib As Second-Line Therapy and in Persistent Immune Thrombocytopenia (ITP) Patients

Hyper-Sialylated IgG M254, an Innovative Therapeutic Candidate, Evaluated in Healthy Volunteers and in Patients with Immune Thrombocytopenia Purpura: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics

Updated Results from the Single-Arm, Open-Label, Long-Term Efficacy and Safety Study of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP)

Rituximab (Ritux) Maintenance Infusions in Immune Thrombocytopenia (ITP) to Prolong Remission Following Relapse after Initial Ritux Induction but Responded to a Second Course

Therapeutic Plasma Exchange Practices in Immune Thrombocytopenic Purpura Related Hospitalizations: Real World Practices for a Category III Apheresis Indication

Thrombin-Generating Capacity of Microvesicles (MVs) in Patients with Immune Thrombocytopenia (ITP) before and during Treatment with Thrombopoietin-Receptor Agonists (TPO-RA)

Immune Thrombocytopenia Complications: Implications on Length of Stay and and Mortality

Venous Thromboembolism (VTE) in Hematological and Non-Hematological Cancers: A Nationwide Analysis

Predictors of Remission in Adults with Immune Thrombocytopenia Treated with Romiplostim

Two-Year Safety and Efficacy Outcomes with Fostamatinib in Adult Patients with Immune Thrombocytopenia (ITP): Open-Label Extension to Phase 3 Trial Program

Treatment of Immune Thrombocytopenia (ITP) with Eltrombopag (EPAG) in Patients Who Did and Did Not Receive Prior Rituximab (Ritux): A Post-Hoc Analysis of the Extend Study

Medical Decision Analysis: Choosing Second Line Treatment in Adults with Immune Thrombocytopenia (ITP)

Fetal-Neonatal Alloimmune Thrombocytopenia (FNAIT): Guidance to Reduce the Risk of Intracranial Bleeding

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only